TY  - JOUR
AU  - Adžić, Miroslav
AU  - Brkić, Željka
AU  - Mitić, Miloš
AU  - Francija, Ester
AU  - Jovičić, Milica J.
AU  - Radulović, Jelena
AU  - Marić, Nađa P.
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1939
AB  - Background: Mounting evidence demonstrates enhanced systemic levels of inflammatory mediators in depression, indicating that inflammation may play a role in the etiology and course of mood disorders. Indeed, proinflammatory cytokines induce a behavioral state of conservation- withdrawal resembling human depression, characterized by negative mood, fatigue, anhedonia, psychomotor retardation, loss of appetite, and cognitive deficits. Neuroinflammation also contributes to non-responsiveness to current antidepressant (AD) therapies. Namely, response to conventional AD medications is associated with a decrease in inflammatory biomarkers, whereas resistance to treatment is accompanied by increased inflammation. Methods: In this review, we will discuss the utility and shortcomings of pharmacologic AD treatment strategies focused on inflammatory pathways, applied alone or as an adjuvant component to current AD therapies. Results: Mechanisms of cytokine actions on behavior involve activation of inflammatory pathways in the brain, resulting in changes of neurotransmitter metabolism, neuroendocrine function, and neuronal plasticity. Selective serotonin reuptake inhibitors exhibit the most beneficial effects in restraining the inflammation markers in depression. Different anti-inflammatory agents exhibit AD effects via modulating neurotransmitter systems, neuroplasticity markers and glucocorticoid receptor signaling. Anti-inflammatory add-on therapy in depression highlights such treatment as a candidate for enhancement strategy in patients with moderate-to-severe depression. Conclusion: The interactions between the immune system and CNS are not only involved in shaping behavior, but also in responding to therapeutics. Even though, substantial evidence from animal and human research support a beneficial effect of anti-inflammatory add-on therapy in depression, further research with special attention on safety, particularly during prolonged periods of antiinflammatory co-treatments, is required.
T2  - Current Neuropharmacology
T1  - Therapeutic Strategies for Treatment of Inflammation-related Depression
VL  - 16
IS  - 2
SP  - 176
EP  - 209
DO  - 10.2174/1570159X15666170828163048
ER  - 

@article{
author = "Adžić, Miroslav and Brkić, Željka and Mitić, Miloš and Francija, Ester and Jovičić, Milica J. and Radulović, Jelena and Marić, Nađa P.",
year = "2018",
abstract = "Background: Mounting evidence demonstrates enhanced systemic levels of inflammatory mediators in depression, indicating that inflammation may play a role in the etiology and course of mood disorders. Indeed, proinflammatory cytokines induce a behavioral state of conservation- withdrawal resembling human depression, characterized by negative mood, fatigue, anhedonia, psychomotor retardation, loss of appetite, and cognitive deficits. Neuroinflammation also contributes to non-responsiveness to current antidepressant (AD) therapies. Namely, response to conventional AD medications is associated with a decrease in inflammatory biomarkers, whereas resistance to treatment is accompanied by increased inflammation. Methods: In this review, we will discuss the utility and shortcomings of pharmacologic AD treatment strategies focused on inflammatory pathways, applied alone or as an adjuvant component to current AD therapies. Results: Mechanisms of cytokine actions on behavior involve activation of inflammatory pathways in the brain, resulting in changes of neurotransmitter metabolism, neuroendocrine function, and neuronal plasticity. Selective serotonin reuptake inhibitors exhibit the most beneficial effects in restraining the inflammation markers in depression. Different anti-inflammatory agents exhibit AD effects via modulating neurotransmitter systems, neuroplasticity markers and glucocorticoid receptor signaling. Anti-inflammatory add-on therapy in depression highlights such treatment as a candidate for enhancement strategy in patients with moderate-to-severe depression. Conclusion: The interactions between the immune system and CNS are not only involved in shaping behavior, but also in responding to therapeutics. Even though, substantial evidence from animal and human research support a beneficial effect of anti-inflammatory add-on therapy in depression, further research with special attention on safety, particularly during prolonged periods of antiinflammatory co-treatments, is required.",
journal = "Current Neuropharmacology",
title = "Therapeutic Strategies for Treatment of Inflammation-related Depression",
volume = "16",
number = "2",
pages = "176-209",
doi = "10.2174/1570159X15666170828163048"
}

Adžić, M., Brkić, Ž., Mitić, M., Francija, E., Jovičić, M. J., Radulović, J.,& Marić, N. P.. (2018). Therapeutic Strategies for Treatment of Inflammation-related Depression. in Current Neuropharmacology, 16(2), 176-209.
https://doi.org/10.2174/1570159X15666170828163048

Adžić M, Brkić Ž, Mitić M, Francija E, Jovičić MJ, Radulović J, Marić NP. Therapeutic Strategies for Treatment of Inflammation-related Depression. in Current Neuropharmacology. 2018;16(2):176-209.
doi:10.2174/1570159X15666170828163048 .

Adžić, Miroslav, Brkić, Željka, Mitić, Miloš, Francija, Ester, Jovičić, Milica J., Radulović, Jelena, Marić, Nađa P., "Therapeutic Strategies for Treatment of Inflammation-related Depression" in Current Neuropharmacology, 16, no. 2 (2018):176-209,
https://doi.org/10.2174/1570159X15666170828163048 . .

TY  - JOUR
AU  - Jovičić, Milica J.
AU  - Lukić, Iva
AU  - Radojčić, Marija
AU  - Adžić, Miroslav
AU  - Marić, Nađa P.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/723
AB  - Glucocorticoid resistance is a common finding in major depressive disorder. Increased glucocorticoid receptor (GR) phosphorylation at serine 226 is associated with increased glucocorticoid resistance. Previously we have demonstrated that depressed patients exhibit higher levels of GR phosphorylated at serine 226 compared to healthy controls. The enzyme that is involved in this specific GR phosphorylation is c-Jun N-terminal kinase (JNK). We propose that modulation of glucocorticoid phosphorylation at serine 226, by targeting JNK signaling pathway, could be a potential strategy for antidepressant treatment. We base this assumption on the results of previous research that examined GR phosphorylation and JNK signaling in animal models and human studies. We also discuss the potential challenges in targeting JNK signaling pathway in depression. (C) 2015 Elsevier Ltd. All rights reserved.
T2  - Medical Hypotheses
T1  - Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression
VL  - 85
IS  - 3
SP  - 291
EP  - 294
DO  - 10.1016/j.mehy.2015.05.015
ER  - 

@article{
author = "Jovičić, Milica J. and Lukić, Iva and Radojčić, Marija and Adžić, Miroslav and Marić, Nađa P.",
year = "2015",
abstract = "Glucocorticoid resistance is a common finding in major depressive disorder. Increased glucocorticoid receptor (GR) phosphorylation at serine 226 is associated with increased glucocorticoid resistance. Previously we have demonstrated that depressed patients exhibit higher levels of GR phosphorylated at serine 226 compared to healthy controls. The enzyme that is involved in this specific GR phosphorylation is c-Jun N-terminal kinase (JNK). We propose that modulation of glucocorticoid phosphorylation at serine 226, by targeting JNK signaling pathway, could be a potential strategy for antidepressant treatment. We base this assumption on the results of previous research that examined GR phosphorylation and JNK signaling in animal models and human studies. We also discuss the potential challenges in targeting JNK signaling pathway in depression. (C) 2015 Elsevier Ltd. All rights reserved.",
journal = "Medical Hypotheses",
title = "Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression",
volume = "85",
number = "3",
pages = "291-294",
doi = "10.1016/j.mehy.2015.05.015"
}

Jovičić, M. J., Lukić, I., Radojčić, M., Adžić, M.,& Marić, N. P.. (2015). Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression. in Medical Hypotheses, 85(3), 291-294.
https://doi.org/10.1016/j.mehy.2015.05.015

Jovičić MJ, Lukić I, Radojčić M, Adžić M, Marić NP. Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression. in Medical Hypotheses. 2015;85(3):291-294.
doi:10.1016/j.mehy.2015.05.015 .

Jovičić, Milica J., Lukić, Iva, Radojčić, Marija, Adžić, Miroslav, Marić, Nađa P., "Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression" in Medical Hypotheses, 85, no. 3 (2015):291-294,
https://doi.org/10.1016/j.mehy.2015.05.015 . .